Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231631 | 0.87 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4GFER | |
| SCHEMBL2998895 | 0.83 | KMT2A (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4GFER | |
| Trifluoroacetic Acid SCHEMBL3000870 | 0.80 | SLC2A1 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4SLC2A1 | |
| SCHEMBL5442308 | 0.78 | PRKCA (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4P2RY12 | |
| SCHEMBL4868398 | 0.78 | HDAC1 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4PKM | |
| SCHEMBL2992082 | 0.77 | SIGMAR1 (0.37) | — | |
| SCHEMBL2992969 | 0.75 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4GFER | |
| SCHEMBL4877253 | 0.73 | KCNH2 (0.39) | — | |
| SCHEMBL2998890 | 0.71 | BACE1 (0.39) | TACR1 | |
| SCHEMBL4873846 | 0.70 | GHSR (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2009-02-05 | — | — | US | claimed |
| US-7781431-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-08-24 | — | — | US | disclosed |
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2009-02-05 | — | — | US | disclosed |
| EP-1664059-B1 | THIENOPYRROLES AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ZC3HAV1, XDH, TPMT | CHRNB2 3899/4885CHRNB4 3325/4885CHRNA3 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.